TP53 and acute myeloid leukemia: In the latter study, the majority of patients (84%) with TP53-mutated AML/MDS-EB had complex karyotype (i.e., ≥3 concurrent cytogenetic abnormalities) and CK was even more commonly observed in patients with bi-allelic TP53 mutations (97%), multiple TP53 mutations (94%), and in patients with larger TP53-mutated clones (94%, defined by variant allele frequency of >40%) [6].